PTTG1 and breast carcinoma: In our sample, a 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer (P=0.0218) and a 7.1-fold risk for patients with securin immunopositivity above 20% compared to below 10% (P=0.0270).